Login to Your Account

Treatment Superior to Vancocin

Positive Data in C. Difficile Send Optimer Shares Soaring

By Jennifer Boggs

Wednesday, November 12, 2008
Much awaited data from Optimer Pharmaceuticals Inc.'s pivotal study of macrocyclic antibiotic OPT-80 in the troublesome Clostridium difficile-based infection space did not disappoint investors, as top-line results showed that the drug not only met the primary endpoint of noninferiority compared to Vancocin but actually demonstrated superior activity to the marketed drug. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription